Our earlier study demonstrated that ADT activates ZBTB46, a prostatic tumor promoter, which promotes the epithelial–mesenchymal transition through transcriptional regulation of SNAI123 and is associated with neuroendocrine differentiation and tumor recurrence in prostate cancer after ADT24. The gene discussed is ZBTB46; the disease is prostate carcinoma.